Effect of thromboxane A2 synthetase inhibitor on immediate-type hypersensitivity reactions.
The effect of the thromboxane (TX) A2 synthetase inhibitor, OKY-046, on human leukocyte histamine release and bronchial hypersensitivity in asthmatic subjects was evaluated. It was found that OKY-046 inhibited IgE- and Ca2+ ionophore A23187-mediated leukocyte histamine release in a dose-dependent fashion (IC50: 1.0 and 3.0 X 10(-3) M, respectively) and that OKY-046 could diminish bronchial hypersensitivity, determined by leukotriene D4 inhalation, following a 2-week oral medication. These data suggest that the TXA2 synthetase inhibitor can produce favorable effects upon the course of immediate-type hypersensitivity reactions.
D000179:Acrylates / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D000001:Calcimycin / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007073:Immunoglobulin E / Q000276:immunology; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008689:Methacrylates / Q000494:pharmacology / Q000627:therapeutic use*; D013189:SRS-A; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D008689:Methacrylates; D013189:SRS-A; D007073:Immunoglobulin E; D000001:Calcimycin; D013930:Thromboxane-A Synthase; C034364:ozagrel